A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on the preclinical work demonstrating that bendamustine...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400650/
https://ncbi.nlm.nih.gov/pubmed/27655665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12054
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky